Neurizon Therapeutics Limited has released a press release.
PharmAust Shareholder Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- Monepantel Anti-viral Activity Against SARS-CoV-2 Confirmed
- Elanco Option Update
- Epichem in partnership to develop waste into fuel technology
- Appendix 4E & Preliminary Final Report
- Inhibition of SARS-CoV-2 by MPL in Human Respiratory Cells
Later from Neurizon Therapeutics
- PAA awarded grant for Phase I trial in Motor Neurone Disease
- PAA Evaluate MPL Suitability for Ex-Vivo Human COVID-19 Test
- ONJCRI Evaluates Monepantel Anti-Cancer Mechanism
- PharmAust to Commence Phase IIb Dog Cancer Trial
- PAA Commences Manufacture of GMP-Grade MPL for Human Trials
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics